Secondary resistance to idelalisib is characterized by upregulation of IGF1R rather than by MAPK/ERK pathway mutations.
作者信息
Tausch Eugen, Ljungström Viktor, Agathangelidis Andreas, Zapatka Marc, Scarfò Lydia, Jebaraj Billy Michael Chelliah, Yosifov Deyan Y, Müller Annika, Munugalavadla Veerendra, Degenhardt Jeremiah D, Ghia Paolo, Rosenquist Richard, Stilgenbauer Stephan
机构信息
Division of Chronic Lymphocytic Leukemia, Department of Internal Medicine III, Ulm University, Ulm, Germany.
Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
出版信息
Blood. 2022 Jun 2;139(22):3340-3344. doi: 10.1182/blood.2021014550.
PMID:35377939
Abstract
摘要
Zotero 插件